vs

Side-by-side financial comparison of Sunrun Inc. (RUN) and West Pharmaceutical Services (WST). Click either name above to swap in a different company.

Sunrun Inc. is the larger business by last-quarter revenue ($1.2B vs $805.0M, roughly 1.4× West Pharmaceutical Services). West Pharmaceutical Services runs the higher net margin — 16.4% vs 8.9%, a 7.5% gap on every dollar of revenue. On growth, Sunrun Inc. posted the faster year-over-year revenue change (123.5% vs 7.5%). Over the past eight quarters, Sunrun Inc.'s revenue compounded faster (59.0% CAGR vs 7.6%).

Sunrun Inc. is an American provider of photovoltaic systems and battery energy storage products, primarily for residential customers. The company was established in 2007 and is headquartered in San Francisco, California.

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.

RUN vs WST — Head-to-Head

Bigger by revenue
RUN
RUN
1.4× larger
RUN
$1.2B
$805.0M
WST
Growing faster (revenue YoY)
RUN
RUN
+116.0% gap
RUN
123.5%
7.5%
WST
Higher net margin
WST
WST
7.5% more per $
WST
16.4%
8.9%
RUN
Faster 2-yr revenue CAGR
RUN
RUN
Annualised
RUN
59.0%
7.6%
WST

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RUN
RUN
WST
WST
Revenue
$1.2B
$805.0M
Net Profit
$103.6M
$132.1M
Gross Margin
37.8%
Operating Margin
8.4%
19.5%
Net Margin
8.9%
16.4%
Revenue YoY
123.5%
7.5%
Net Profit YoY
103.7%
1.5%
EPS (diluted)
$0.38
$1.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RUN
RUN
WST
WST
Q4 25
$1.2B
$805.0M
Q3 25
$724.6M
$804.6M
Q2 25
$569.3M
$766.5M
Q1 25
$504.3M
$698.0M
Q4 24
$518.5M
$748.8M
Q3 24
$537.2M
$746.9M
Q2 24
$523.9M
$702.1M
Q1 24
$458.2M
$695.4M
Net Profit
RUN
RUN
WST
WST
Q4 25
$103.6M
$132.1M
Q3 25
$16.6M
$140.0M
Q2 25
$279.8M
$131.8M
Q1 25
$50.0M
$89.8M
Q4 24
$-2.8B
$130.1M
Q3 24
$-83.8M
$136.0M
Q2 24
$139.1M
$111.3M
Q1 24
$-87.8M
$115.3M
Gross Margin
RUN
RUN
WST
WST
Q4 25
37.8%
Q3 25
36.6%
Q2 25
35.7%
Q1 25
33.2%
Q4 24
36.5%
Q3 24
35.4%
Q2 24
32.8%
Q1 24
33.1%
Operating Margin
RUN
RUN
WST
WST
Q4 25
8.4%
19.5%
Q3 25
0.5%
20.8%
Q2 25
-19.7%
20.1%
Q1 25
-22.8%
15.3%
Q4 24
-628.0%
21.3%
Q3 24
-23.8%
21.6%
Q2 24
-24.4%
18.0%
Q1 24
-40.0%
17.7%
Net Margin
RUN
RUN
WST
WST
Q4 25
8.9%
16.4%
Q3 25
2.3%
17.4%
Q2 25
49.1%
17.2%
Q1 25
9.9%
12.9%
Q4 24
-542.7%
17.4%
Q3 24
-15.6%
18.2%
Q2 24
26.5%
15.9%
Q1 24
-19.2%
16.6%
EPS (diluted)
RUN
RUN
WST
WST
Q4 25
$0.38
$1.82
Q3 25
$0.06
$1.92
Q2 25
$1.07
$1.82
Q1 25
$0.20
$1.23
Q4 24
$-12.59
$1.78
Q3 24
$-0.37
$1.85
Q2 24
$0.55
$1.51
Q1 24
$-0.40
$1.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RUN
RUN
WST
WST
Cash + ST InvestmentsLiquidity on hand
$791.3M
Total DebtLower is stronger
$14.7B
$202.8M
Stockholders' EquityBook value
$3.1B
$3.2B
Total Assets
$22.6B
$4.3B
Debt / EquityLower = less leverage
4.69×
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RUN
RUN
WST
WST
Q4 25
$791.3M
Q3 25
$628.5M
Q2 25
$509.7M
Q1 25
$404.2M
Q4 24
$484.6M
Q3 24
$490.9M
Q2 24
$446.2M
Q1 24
$601.8M
Total Debt
RUN
RUN
WST
WST
Q4 25
$14.7B
$202.8M
Q3 25
$14.6B
$202.7M
Q2 25
$14.0B
$202.6M
Q1 25
$13.6B
$202.6M
Q4 24
$12.9B
$202.6M
Q3 24
$12.5B
$202.6M
Q2 24
$12.0B
$205.8M
Q1 24
$11.1B
$206.2M
Stockholders' Equity
RUN
RUN
WST
WST
Q4 25
$3.1B
$3.2B
Q3 25
$3.0B
$3.1B
Q2 25
$2.9B
$2.9B
Q1 25
$2.6B
$2.7B
Q4 24
$2.6B
$2.7B
Q3 24
$5.3B
$2.8B
Q2 24
$5.4B
$2.6B
Q1 24
$5.2B
$2.7B
Total Assets
RUN
RUN
WST
WST
Q4 25
$22.6B
$4.3B
Q3 25
$22.2B
$4.1B
Q2 25
$21.2B
$4.0B
Q1 25
$20.4B
$3.6B
Q4 24
$19.9B
$3.6B
Q3 24
$22.1B
$3.7B
Q2 24
$21.4B
$3.5B
Q1 24
$20.8B
$3.6B
Debt / Equity
RUN
RUN
WST
WST
Q4 25
4.69×
0.06×
Q3 25
4.90×
0.07×
Q2 25
4.80×
0.07×
Q1 25
5.19×
0.08×
Q4 24
5.05×
0.08×
Q3 24
2.36×
0.07×
Q2 24
2.23×
0.08×
Q1 24
2.15×
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RUN
RUN
WST
WST
Operating Cash FlowLast quarter
$96.9M
$251.1M
Free Cash FlowOCF − Capex
$175.0M
FCF MarginFCF / Revenue
21.7%
Capex IntensityCapex / Revenue
9.5%
Cash ConversionOCF / Net Profit
0.94×
1.90×
TTM Free Cash FlowTrailing 4 quarters
$468.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RUN
RUN
WST
WST
Q4 25
$96.9M
$251.1M
Q3 25
$-121.5M
$197.2M
Q2 25
$-292.7M
$177.1M
Q1 25
$-104.2M
$129.4M
Q4 24
$-258.4M
$190.1M
Q3 24
$-156.2M
$180.1M
Q2 24
$-208.5M
$165.0M
Q1 24
$-143.1M
$118.2M
Free Cash Flow
RUN
RUN
WST
WST
Q4 25
$175.0M
Q3 25
$133.9M
Q2 25
$101.9M
Q1 25
$58.1M
Q4 24
$85.2M
Q3 24
$-156.4M
$98.8M
Q2 24
$64.8M
Q1 24
$27.6M
FCF Margin
RUN
RUN
WST
WST
Q4 25
21.7%
Q3 25
16.6%
Q2 25
13.3%
Q1 25
8.3%
Q4 24
11.4%
Q3 24
-29.1%
13.2%
Q2 24
9.2%
Q1 24
4.0%
Capex Intensity
RUN
RUN
WST
WST
Q4 25
9.5%
Q3 25
7.9%
Q2 25
9.8%
Q1 25
10.2%
Q4 24
14.0%
Q3 24
0.0%
10.9%
Q2 24
14.3%
Q1 24
13.0%
Cash Conversion
RUN
RUN
WST
WST
Q4 25
0.94×
1.90×
Q3 25
-7.33×
1.41×
Q2 25
-1.05×
1.34×
Q1 25
-2.08×
1.44×
Q4 24
1.46×
Q3 24
1.32×
Q2 24
-1.50×
1.48×
Q1 24
1.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RUN
RUN

Products$692.3M60%
Customer Agreements$435.2M38%
Manufactured Product Other$56.7M5%
Incentives$31.3M3%

WST
WST

Proprietary Products$661.8M82%
Contract Manufactured Products$143.2M18%
Affiliated Entity$3.3M0%

Related Comparisons